Pfizer-COVID-19 Vaccine

Phase 3Vaccine

Moderna

Pfizer-COVID-19 Vaccine is one of 62 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

COVID-19Active, not recruiting

LymphomaPhase 3

Recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Pfizer-COVID-19 Vaccine

Moderna

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

ApprovedRecruiting

Lymphoma

NCT05170399

Clinical

Trials by Indication[1]

COVID-191 trial

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

Completed· Moderna logo

Moderna··NCT05765578·1,713 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pfizer-COVID-19 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pfizer-COVID-19 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pfizer-COVID-19 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Moderna

Pfizer-COVID-19 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

COVID-191 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News